AIM ImmunoTech (AIM) 10-Q 14 Nov 24 2024 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2024	Nov. 11, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2024
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--12-31
Entity File Number	001-27072
Entity Registrant Name	AIM IMMUNOTECH INC.
Entity Central Index Key	0000946644
Entity Tax Identification Number	52-0845822
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	2117 SW Highway 484
Entity Address, City or Town	Ocala
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	34473
City Area Code	(352)
Local Phone Number	448-7797
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	AIM
Security Exchange Name	NYSEAMER
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		63,706,446

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 915,000	$ 5,439,000
Marketable securities	6,287,000	7,631,000
Funds receivable from New Jersey net operating loss		1,184,000
Prepaid expenses and other current assets	368,000	302,000
Total current assets	7,570,000	14,556,000
Property and equipment, net	117,000	127,000
Right of use asset, net	653,000	697,000
Patent and trademark rights, net	2,532,000	2,313,000
Other assets	2,716,000	1,688,000
Total assets	13,588,000	19,381,000
Current liabilities:
Accounts payable	6,264,000	6,443,000
Accrued expenses	1,011,000	1,986,000
Current portion of operating lease liability	232,000	223,000
Current portion of note payable, net	2,593,000
Total current liabilities	10,100,000	8,652,000
Long-term liabilities:
Operating lease liability	437,000	495,000
Note payable, net	139,000
Total liabilities	10,676,000	9,147,000
Commitments and contingencies (Notes 13 and 14)
Stockholders’ equity:
Common Stock, $0.001 par value, authorized shares - 350,000,000; issued and outstanding shares 58,668,647 and 49,102,484 as of September 30, 2024 and December 31, 2023, respectively	59,000	49,000
Additional paid-in capital	423,714,000	419,004,000
Accumulated deficit	(420,861,000)	(409,508,000)
Total stockholders’ equity	2,912,000	10,234,000
Total liabilities and stockholders’ equity	13,588,000	19,381,000
Series A Junior Participating Preferred Stock [Member]
Stockholders’ equity:
Convertible preferred stock, value
Series B Convertible Preferred Stock [Member]
Stockholders’ equity:
Convertible preferred stock, value		$ 689,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2024	Dec. 31, 2023
Preferred stock, par value	$ 0.01
Preferred stock, shares authorized	5,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	350,000,000	350,000,000
Common stock, shares issued	58,668,647	49,102,484
Common stock, shares outstanding	58,668,647	49,102,484
Series A Junior Participating Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	4,000,000	250,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Series B Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.01
Preferred stock, shares authorized	10,000	10,000
Preferred stock, shares issued	0	689
Preferred stock, shares outstanding	0	689
Preferred stock, stated value	$ 1,000	$ 1,000

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenues:
Clinical treatment programs - US	$ 35	$ 46	$ 125	$ 137
Total Revenues	35	46	125	137
Costs and Expenses:
Production costs	8	30	24	30
Research and development	1,437	2,734	4,533	7,739
General and administrative	3,079	5,439	9,485	10,280
Total Costs and Expenses	4,524	8,203	14,042	18,049
Operating loss	(4,489)	(8,157)	(13,917)	(17,912)
Gain (loss) on investments	273	(310)	96	(201)
Interest and other income	718	294	3,379	811
Interest expense and other finance costs	(202)		(453)
Gain on sale of fixed assets		39		16
(Loss) on warrant issuance			(458)
Gain from sale of income tax operating losses		318		900
Net Loss	$ (3,700)	$ (7,816)	$ (11,353)	$ (16,386)
Basic loss per share	$ (0.06)	$ (0.16)	$ (0.21)	$ (0.34)
Diluted loss per share	$ (0.06)	$ (0.16)	$ (0.21)	$ (0.34)
Weighted average shares outstanding basic	57,677,016	48,635,165	53,351,467	48,483,802
Weighted average shares outstanding diluted	57,677,016	48,635,165	53,351,467	48,483,802

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Preferred Stock [Member] Series B Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2022	$ 696	$ 48	$ 418,270		$ (380,546)	$ 38,468
Balance, shares at Dec. 31, 2022		48,084,287
Common stock issuance, net of costs			100			100
Common stock issuance, net of costs, shares		322,583
Net Comprehensive loss					(3,661)	(3,661)
Equity-based compensation			82			82
Series B preferred shares converted to common shares	(4)		4
Series B preferred shares converted to common shares, shares		456
Balance at Mar. 31, 2023	692	$ 48	418,456		(384,207)	34,989
Balance, shares at Mar. 31, 2023		48,407,326
Balance at Dec. 31, 2022	696	$ 48	418,270		(380,546)	38,468
Balance, shares at Dec. 31, 2022		48,084,287
Balance at Sep. 30, 2023	690	$ 48	418,796		(396,932)	22,602
Balance, shares at Sep. 30, 2023		48,797,450
Balance at Mar. 31, 2023	692	$ 48	418,456		(384,207)	34,989
Balance, shares at Mar. 31, 2023		48,407,326
Common stock issuance, net of costs			5			5
Common stock issuance, net of costs, shares		11,937
Net Comprehensive loss					(4,909)	(4,909)
Equity-based compensation			50			50
Series B preferred shares converted to common shares	(2)		2
Series B preferred shares converted to common shares, shares		228
Balance at Jun. 30, 2023	690	$ 48	418,513		(389,116)	30,135
Balance, shares at Jun. 30, 2023		48,419,491
Common stock issuance, net of costs			233			233
Common stock issuance, net of costs, shares		377,959
Net Comprehensive loss					(7,816)	(7,816)
Equity-based compensation			50			50
Series B preferred shares converted to common shares
Balance at Sep. 30, 2023	690	$ 48	418,796		(396,932)	22,602
Balance, shares at Sep. 30, 2023		48,797,450
Balance at Dec. 31, 2023	689	$ 49	419,004		(409,508)	10,234
Balance, shares at Dec. 31, 2023		49,102,484
Common stock issuance, net of costs		$ 1	328			329
Common stock issuance, net of costs, shares		807,577
Cashless exercise of warrants
Cashless Exercise of Warrants, shares		3,272
Equity-based compensation			80			80
Committed shares
Committed Shares, shares		338,600
Net Comprehensive loss					(5,817)	(5,817)
Balance at Mar. 31, 2024	689	$ 50	419,412		(415,325)	4,826
Balance, shares at Mar. 31, 2024		50,251,933
Balance at Dec. 31, 2023	689	$ 49	419,004		(409,508)	10,234
Balance, shares at Dec. 31, 2023		49,102,484
Balance at Sep. 30, 2024		$ 59	423,714		(420,861)	2,912
Balance, shares at Sep. 30, 2024		58,668,647
Balance at Mar. 31, 2024	689	$ 50	419,412		(415,325)	4,826
Balance, shares at Mar. 31, 2024		50,251,933
Common stock issuance, net of costs		$ 7	525			532
Common stock issuance, net of costs, shares		6,884,747
Equity-based compensation			80			80
Net Comprehensive loss					(1,836)	(1,836)
Issuance of warrants			2,500			2,500
Series B preferred shares expired	(689)		689
Balance at Jun. 30, 2024		$ 57	423,206		(417,161)	6,102
Balance, shares at Jun. 30, 2024		57,136,680
Common stock issuance, net of costs		$ 1	179			180
Common stock issuance, net of costs, shares		653,430
Net Comprehensive loss					(3,700)	(3,700)
Issuance of warrants
Series B preferred shares expired
Equity-based compensation		$ 1	329			330
Equity-based compensation, shares		878,537
Balance at Sep. 30, 2024		$ 59	$ 423,714		$ (420,861)	$ 2,912
Balance, shares at Sep. 30, 2024		58,668,647

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities:
Net loss	$ (11,353,000)	$ (16,386,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of property and equipment	28,000	30,000
Abandonment of patent and trademark rights	46,000	14,000
Amortization of patent, trademark rights	154,000	150,000
Changes in right of use assets	226,000	151,000
Gain from sale of income tax operating losses		(900,000)
Equity-based compensation	490,000	182,000
(Gain) loss on sale of marketable securities	(95,000)	201,000
Loss on issuance of warrants	458,000
Amortization of financial obligation	232,000
Change in assets and liabilities:
Other receivables		(9,000)
Funds receivable from New Jersey net operating loss	1,181,000	1,676,000
Prepaid expenses and other current assets and other non-current assets	(63,000)	192,000
Lease liability	(231,000)	(136,000)
Other assets	(1,028,000)
Accounts payable	(179,000)	2,411,000
Accrued expenses	(799,000)	915,000
Net cash used in operating activities	(10,933,000)	(11,509,000)
Cash flows from investing activities:
Proceeds from sale of marketable securities	1,597,000	924,000
Purchase of marketable securities	(158,000)	(1,155,000)
(Purchase of) property and equipment	(18,000)	(10,000)
Purchase of patent and trademark rights	(419,000)	(377,000)
Net cash provided by (used in) investing activities	1,002,000	(618,000)
Cash flows from financing activities:
Proceeds from sale of stock, net of issuance costs	860,000	338,000
Proceeds from note payable, net of issuance costs	2,500,000
Proceeds from issuance of equity warrants	2,047,000
Net cash provided by financing activities	5,407,000	338,000
Net decrease in cash and cash equivalents	(4,524,000)	(11,789,000)
Cash and cash equivalents at beginning of period	5,439,000	27,053,000
Cash and cash equivalents at end of period	915,000	15,264,000
Supplemental disclosures of non-cash investing and financing cash flow information:
Operating lease-Right of Use Assets	(3,000)	49,000
Unrealized gain (loss) on marketable securities	373,000	(71,000)
Conversion of Series B preferred		6,000
Conversion of note payable interest into shares	$ 175,000

Business and Basis of Presentat

Business and Basis of Presentation	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Business and Basis of Presentation	Note 1: Business and Basis of Presentation AIM ImmunoTech Inc. and its subsidiaries (collectively, “AIM”, “Company”, “we” or “us”) are an immuno-pharma company headquartered in Ocala, Florida, focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases and immune-deficiency disorders. We have established a strong foundation of laboratory, pre-clinical and clinical data with respect to the development of nucleic acids and natural interferon to enhance the natural antiviral defense system of the human body, and to aid the development of therapeutic products for the treatment of certain cancers and chronic diseases. AIM’s flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (“dsRNA”) molecule being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen has not been approved by the FDA or marketed in the United States but is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (“CFS”). The Company is currently proceeding primarily in four areas: ● Conducting clinical trials to evaluate the efficacy and safety of Ampligen for the treatment of pancreatic cancer. ● Evaluating Ampligen across multiple cancers as a potential therapy that modifies the tumor microenvironment with the goal of increasing anti-tumor responses to checkpoint inhibitors. ● Exploring Ampligen’s antiviral activities and potential use as a prophylactic or treatment for existing viruses, new viruses and mutated viruses thereof. ● Evaluating Ampligen as a treatment for myalgic encephalomyelitis/chronic fatigue syndrome (“ME/CFS”) and fatigue and/or the Post-COVID condition of fatigue. The Company is prioritizing activities in an order related to the stage of development, with those clinical activities such as pancreatic cancer, ME/CFS and Post-COVID conditions having priority over antiviral experimentation. The Company intends that priority clinical work be conducted in trials authorized by the FDA or European Medicines Agency (“EMA”), which trials support a potential future NDA. However, AIM’s antiviral experimentation is designed to accumulate additional preliminary data supporting their hypothesis that Ampligen is a powerful, broad-spectrum prophylaxis and early-onset therapeutic that may confer enhanced immunity and cross-protection. Accordingly, AIM will conduct antiviral programs in those venues most readily available and able to generate valid proof-of-concept data, including foreign venues. AIM’s business plan requires one or more Contract Manufacturing Organizations (“CMO”) to produce Ampligen and its Active Pharmaceutical Ingredients (APIs). This includes utilizing Jubilant HollisterStier and Sterling for the manufacture of Ampligen and our Poly I and Poly C12U polynucleotides, respectively. In the opinion of management, all adjustments necessary for a fair presentation of its consolidated financial statements have been included. Such adjustments consist of normal recurring items. Interim results are not necessarily indicative of results for a full year. The interim consolidated financial statements and notes thereto are presented as permitted by the Securities and Exchange Commission (“SEC”), and do not contain certain information which will be included in the Company’s annual consolidated financial statements and notes thereto. These consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements for the years ended December 31, 2023, and 2022, contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed on April 1, 2024. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure (“GAAP”) of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the reporting period. Actual results could differ from those estimates, and those differences may be material. Accounts requiring the use of significant estimates include determination of other-than-temporary impairment on securities, valuation of deferred taxes, patent and trademark valuations, stock-based compensation calculations, fair value of warrants, and contingency accruals. Liquidity and Going Concern The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The going concern basis of presentation assumes that the Company will continue in operation one year after the date these financial statements are issued and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business. Pursuant to the requirements of the Financial Accounting Standards Board’s (the “FASB”) Accounting Standards Codification (“ASC”) Topic 205-40, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern for one year from the date these financial statements are issued. This evaluation does not take into consideration the potential mitigating effect of management’s plans that have not been fully implemented or are not within control of the Company as of the date the financial statements are issued. When substantial doubt about the Company’s ability to continue as a going concern exists, management evaluates whether the mitigating effect of its plans sufficiently alleviates the substantial doubt. The mitigating effect of management’s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. The Company’s principal source of liquidity is its cash and cash equivalents, marketable securities, and proceeds from financing activities to provide the necessary funding to meet our obligations as they become due. The Company has suffered losses from operations and net cash used on operating activities for the nine-month period ended September 30, 2024, and has a working capital deficit as of September 30, 2024. Additionally, the Company’s stockholders’ equity was below the minimum requirements for continued listing on the New York Stock Exchange American (“NYSE American”). These conditions raise substantial doubt regarding the Company’s ability to continue as a going concern for a period of at least one year from the date of issuance of these unaudited condensed consolidated financial statements. Management evaluated the conditions, and the significance of these conditions related to the Company’s ability to meet its obligations and determined that the primary cause of the deficit was related to certain accounts payable which the Company is currently in negotiations with the vendor. These negotiations are ongoing and could result in significant amounts which could partially alleviate the negative working capital. There is no assurance as to the timing or outcome of these efforts. If the Company is unable to implement sufficient mitigation efforts, the Company may be forced to limit its business activities or be unable to continue as a going concern, which would have a material adverse effect on its results of operations and financial condition.

Cash and Cash Equivalents

Cash and Cash Equivalents	9 Months Ended
	Sep. 30, 2024
Cash and Cash Equivalents [Abstract]
Cash and Cash Equivalents	Note 2 Cash and Cash Equivalents Cash includes bank deposits maintained at several financial institutions. The Company considers highly liquid instruments with an original maturity of three months or less to be cash equivalents. At various times throughout the nine months ended September 30, 2024, some accounts held at financial institutions were in excess of the federally insured limit of $ 250,000

Marketable Securities

Marketable Securities	9 Months Ended
	Sep. 30, 2024
Investments, Debt and Equity Securities [Abstract]
Marketable Securities	Note 3: Marketable Securities Marketable securities consist of mutual funds. At September 30, 2024 and December 31, 2023, it was determined that none of the marketable securities had an other-than-temporary impairment. At September 30, 2024 and December 31, 2023, all securities were measured as Level 1 instruments of the fair value measurements standard (See Note 12: Fair Value). At September 30, 2024, and December 31, 2023 the Company held $ 6,287,000 7,631,000 Mutual Funds classified as available for sale consisted of $ 6,287,000 The net gain recognized for the three-month period ended September 30, 2024 on equity securities was $273,000. The net losses recognized for the three-month period ended September 30, 2024 on equity securities sold during the period were ($59,000). The unrealized gains recognized for the three-month period ended September 30, 2024 on equity securities still held was $332,000. The net gain recognized for the nine-month period ended September 30, 2024 on equity securities was $96,000. The net losses recognized for the nine-month period ended September 30, 2024 on equity securities sold during the period were ($277,000). The unrealized gains recognized for the nine-month period ended September 30, 2024 on equity securities still held was $373,000. Mutual Funds classified as available for sale consisted of $ 7,631,000 The net loss recognized for the three-month period ended September 30, 2023 on equity securities was ($309,000). The net losses recognized for the three-month period ended September 30, 2023 on equity securities sold during the period were ($42,000). The unrealized losses recognized during the three-month period ended September 30, 2023 on equity securities still held was ($267,000). The net losses recognized for the nine-month period ended September 30, 2023 on equity securities was ($201,000). The net losses recognized for the nine-month period ended September 30, 2023 on equity securities sold during the period were ($130,000). The unrealized losses recognized during the nine-month period ended September 30, 2023 on equity securities still held was ($71,000).

Property and Equipment, net

Property and Equipment, net	9 Months Ended
	Sep. 30, 2024
Property, Plant and Equipment [Abstract]
Property and Equipment, net	Note 4: Property and Equipment, net Schedule of Property and Equipment (in thousands) September 30, 2024 December 31, 2023 Furniture, fixtures, and equipment 1,466 1,448 Less: accumulated depreciation (1,349 ) (1,321 ) Property and equipment, net $ 117 $ 127 Property and equipment are recorded at cost. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the respective assets, ranging from three ten years 28,000 30,000

Patents, and Trademark Rights,

Patents, and Trademark Rights, Net	9 Months Ended
	Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Patents, and Trademark Rights, Net	Note 5: Patents, and Trademark Rights, Net Patent and trademark rights consist of the following (in thousands): Schedule of Patent and Trademark Rights September 30, 2024 December 31, 2023 Gross Carrying Value Accumulated Amortization Net Carrying Value Gross Carrying Value Accumulated Amortization Net Carrying Value Patents $ 3,315 $ (887 ) $ 2,428 $ 2,947 $ (750 ) $ 2,197 Trademarks 232 (128 ) 104 229 (113 ) 116 Net amortizable patents and trademarks rights $ 3,547 $ (1,015 ) $ 2,532 $ 3,176 $ (863 ) $ 2,313 Patent and trademark rights acquisitions, abandonments and amortization: Schedule of Changes in Patents, Trademark Rights December 31, 2023 $ 2,313 Acquisitions 419 Abandonments and expirations (46 ) Amortization (154 ) September 30, 2024 $ 2,532 Patents and trademarks are stated at cost (primarily legal fees) and are amortized using the straight-line method over an estimated useful life of 17 years 10 years 12 years 6 years Amortization of patents and trademarks for each of the next five years and thereafter is as follows (in thousands): Schedule of Amortization of Patents and Trademarks Year Ending December 31, 2024 $ 72 2025 268 2026 265 2027 239 2028 219 Thereafter 1,469 Total $ 2,532

Accrued Expenses

Accrued Expenses	9 Months Ended
	Sep. 30, 2024
Payables and Accruals [Abstract]
Accrued Expenses	Note 6: Accrued Expenses Accrued expenses consist of the following: Schedule of Accrued Expenses (in thousands) September 30, 2024 December 31, 2023 Compensation $ 1 $ 414 Professional fees 790 1,352 Clinical trial expenses 132 184 Interest 51 — Other expenses 37 36 Total $ 1,011 $ 1,986

Unsecured Promissory Note

Unsecured Promissory Note	9 Months Ended
	Sep. 30, 2024
Debt Disclosure [Abstract]
Unsecured Promissory Note	Note 7: Unsecured Promissory Note On February 16, 2024, the Company (“Borrower”) entered into a Note Purchase Agreement with Streeterville Capital LLC (“Streeterville” or the “Lender”). Under the terms of the agreement, Streeterville paid the Company $ 2,500,000 781,250 3,301,250 20,000 10 no Schedule of Long Term Debt Debt schedule at September 30, 2024 (in thousands) Long-term debt $ 3,301 Unamortized Original issue discount (555 ) Unamortized Financing fees (14 ) Unamortized discount and debt issuance costs 2,732 Less current portion of long-term debt, net (2,593 ) Long-term debt, net $ 139 Interest expense related to long-term debt was $ 226,000 232,000 226,000 6,000 750,000 2,551,000 (1) Current portion of long-term debt of approximately $3,000,000 is net of the current portion of debt discount of approximately $397,000 and the current portion of debt origination costs of approximately $10,000 as of September 30, 2024. (2) Long-term portion of debt of approximately $301,000 is net of the long-term portion of debt discount of approximately $159,000 and the unamortized debt origination costs of approximately $3,000 as of September 30, 2024. Current portion of long-term debt of approximately $ 3,000,000 397,000 10,000 Long-term portion of debt of approximately $ 301,000 159,000 3,000 The agreement allows the Lender to redeem up to $250,000 per calendar month beginning in August 2024, upon providing written notice to Borrower.

Equity-Based Compensation

Equity-Based Compensation	9 Months Ended
	Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]
Equity-Based Compensation	Note 8: Equity-Based Compensation The 2018 Equity Incentive Plan, effective September 12, 2018, as amended and restated on August 19, 2019 (the “2018 Equity Incentive Plan”) authorizes the grant of (i) Incentive Stock Options, (ii) Nonstatutory Stock Options, (iii) Stock Appreciation Rights, (iv) Restricted Stock Awards, (v) Restricted Stock Unit Awards, (vi) Performance Stock Awards, (vii) Performance Cash Awards, and (viii) Other Stock Awards. After taking into account the 44:1 reverse stock split 230,390 250,000 685,012 956,660 960,976 968,389 1,142,733 5,167,160 10 1,189,284 9.68 10 (27,028 options post reverse split) 1,727,756 9.68 ten years one year (39,266 options post reverse split). 1,025,000 2.77 3.07 ten years 613,512 1.11 1.71 ten years 850,000 0.31 0.71 ten years 400,000 0.47 ten years no The fair value of each option and equity warrant award is estimated on the date of grant using a Black-Scholes-Merton option pricing valuation model. Expected volatility is based on the historical volatility of the price of the Company’s stock. The risk-free interest rate is based on U.S. Treasury issues with a term equal to the expected life of the option and equity warrant. The Company uses historical data to estimate expected dividend yield, expected life and forfeiture rates. During the nine months ended September 30, 2024, and 2023, there were no Stock options activity during the three months ended September 30, 2024, was as follows: Stock option activity for employees: Schedule of Stock Option Activity Number of Weighted Weighted Aggregate Outstanding June 30, 2024 2,407,775 $ 2.50 8.70 $ — Granted — — — — Forfeited — — — — Expired (95 ) — — — Outstanding September 30, 2024 2,407,680 $ 2.44 8.70 $ — Vested and expected to vest September 30, 2024 2,407,680 $ 2.44 8.70 $ — Exercisable September 30, 2024 2,341,014 $ 1.66 7.17 $ — Unvested stock option activity for employees: Schedule of Unvested Stock Option Activity Number of Weighted Weighted Aggregate Unvested June 30, 2024 166,666 $ 4.11 18.87 $ — Granted — — — — Expired (95 ) — — — Vested (99,905 ) 0.47 7.17 — Unvested September 30, 2024 66,666 $ 9.61 36.22 $ — Stock option activity for non-employees: Schedule of Stock Option Activity Number of Weighted Weighted Aggregate Outstanding June 30, 2024 885,055 $ 2.02 9.23 $ — Granted — — — — Forfeited — — — — Expired (95 ) — — — Outstanding September 30, 2024 884,960 $ 1.88 9.23 $ — Vested and expected to vest September 30, 2024 884,960 $ 1.88 9.23 $ — Exercisable September 30, 2024 729,960 $ 1.87 10.06 $ — Unvested stock option activity for non-employees: Schedule of Unvested Stock Option Activity Number of Weighted Weighted Aggregate Unvested June 30, 2024 155,001 $ 3.42 11.30 $ — Granted — — — — Expired (95 ) — — — Vested 95 0.46 10.18 — Unvested September 30, 2024 155,001 $ 3.42 11.31 $ — Stock-based compensation expense was approximately $ 80,000 50,000 Employee stock option activity during the nine months ended September 30, 2024, was as follows: Stock option activity for employees: Number of Weighted Weighted Aggregate Outstanding January 1, 2024 2,408,438 $ 2.50 8.70 $ — Granted — — — — Forfeited — — — — Expired (758 ) — — — Outstanding September 30, 2024 2,407,680 $ 2.44 8.70 $ — Vested and expected to vest September 30, 2024 2,407,680 $ 2.44 8.70 $ — Exercisable September 30, 2024 2,341,014 $ 1.66 7.17 $ — Unvested stock option activity for employees: Number of Weighted Weighted Aggregate Unvested January 1, 2024 366,666 $ 2.13 12.44 $ — Granted — — — — Expired (758 ) — — — Vested (299,242 ) 0.47 7.17 — Unvested September 30, 2024 66,666 $ 9.61 36.22 $ — Stock option activity for non-employees: Number of Weighted Weighted Aggregate Outstanding January 1, 2024 885,055 $ 2.02 9.23 $ — Granted — — — — Forfeited — — — — Expired (95 ) — — — Outstanding September 30, 2024 884,960 $ 1.88 9.23 $ — Vested and expected to vest September 30, 2024 884,960 $ 1.88 9.23 $ — Exercisable September 30, 2024 729,960 $ 1.87 10.06 $ — Unvested stock option activity for non-employees: Number of Weighted Weighted Aggregate Unvested January 1, 2024 335,001 $ 1.83 10.70 $ — Granted — — — — Expired (95 ) — — — Vested (179,905 ) 0.46 10.18 — Unvested September 30, 2024 155,001 $ 3.42 11.31 $ — Stock-based compensation expense was approximately $ 490,000 182,000 As part of the Company’s cash conservation strategy, the Company issued common stock as a substitute for cash salaries to certain executives. For the three and nine months ended September 30, 2024, stock issued as payroll totaled $ 250,000 On September 30, 2024, and 2023, respectively, there was approximately $ 53,400 and $ 35,000 of unrecognized equity-based compensation cost related to options granted under the Equity Incentive Plan.

Stockholders_ Equity

Stockholders’ Equity	9 Months Ended
	Sep. 30, 2024
Equity [Abstract]
Stockholders’ Equity	Note 9: Stockholders’ Equity (a) Preferred Stock The Company is authorized to issue 5,000,000 0.01 4,000,000 10,000 Series A Junior Participating Preferred Stock On May 10, 2023, the Company filed a Certificate of Increase in Delaware, increasing the number of preferred stock designated as Series A Junior Participating Preferred Stock to 4,000,000 250,000 Series B Convertible Preferred Stock The Company has designated 10,000 0.01 1,000 Each share of Preferred Stock shall be convertible, at any time and from time to time from and after the Original Issue Date at the option of the Holder thereof or at any time and from time to time on or after the second anniversary of the Original Issue Date at the option of the Corporation, into that number of shares of common stock (subject in each case to the limitations determined by dividing the Stated Value of such share of Preferred Stock by the Conversion Price). The conversion price for the Preferred Stock shall be equal to $ 0.20 Pursuant to a registration statement relating to a rights offering (the “Rights Offering”) declared effective by the SEC on February 14, 2019, AIM distributed to its holders of common stock and to holders of certain options and redeemable warrants as of February 14, 2019, at no charge, one non-transferable subscription right for each share of common stock held or deemed held on the record date. Each right entitled the holder to purchase one unit, at a subscription price of $ 1,000 1,000 8.80 114 8.80 4,700,000 689 (b) Common Stock and Equity Finances The Company has authorized shares of 350,000,000 8,000,000 350,000,000 As of September 30, 2024, and December 31, 2023, there were 58,668,647 49,102,484 Employee Stock Purchase Plan (Not equity compensation) On July 7, 2020, the Board approved a plan pursuant to which all directors, officers, and employees could purchase from the Company up to an aggregate of $ 500,000 During the three months ended September 30, 2024, the Company did no During the nine months ended September 30, 2024, the Company issued a total of 335,603 0.33 0.41 120,000 During the three months ended September 30, 2023, the Company issued a total of 62,841 0.44 0.67 35,500 During the nine months ended September 30, 2023, the Company issued a total of 385,424 0.31 0.67 135,000 Rights Plan On May 12, 2023, the Company amended and restated its November 14, 2017 Rights Plan with American Stock Transfer & Trust Company as Rights Agent (the “Rights Plan”). Warrants (Rights offering) On September 27, 2019, the Company closed a public offering underwritten by A.G.P./Alliance Global Partners, LLC (the “Offering”) of (i) 1,740,550 7,148,310 8,888,860 a Representative’s Warrant to purchase up to an aggregate of 266,665 . The shares of common stock and Warrants were sold at a combined Offering price of $ 0.90 0.99 0.899 4.99 0.001 7,200,000 , 2020, 1,870,000 8,873,960 266,665 264,000 46,000 During the three months ended September 30, 2024, there were no 15,000 205,000 warrants were exercised, and 5,830,028 warrants expired unexercised. As of September 30, 2024 there were no 152,160 post-split warrants outstanding, respectively. Equity Distribution Agreement On April 19, 2023, the Company entered into an Equity Distribution Agreement (the “EDA”) with Maxim Group LLC (“Maxim”), pursuant to which the Company may sell, from time to time, shares of its common stock having an aggregate offering price of up to $ 8,500,000 3.0 598,114 344,000 3.0 10,326 10,975 4,110 3.0 123 1,305,653 630,204 3.0 18,906 Equity Purchase Agreement On March 28, 2024, the Company entered into a purchase agreement and a registration rights agreement with Atlas Sciences, LLC (“Atlas”), pursuant to which Atlas committed to purchase up to $ 15,000,000 Under the terms of the purchase agreement, the Company, at its sole discretion, shall have the right to issue Put shares to the Investor at 95 500,000 4.99 19.99 9,975,000 9,636,400 338,600 759,685 128,000 Securities Purchase Agreement On May 31, 2024, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) to complete an offering (the “Transactions”) with a single accredited investor (the “Purchaser”), pursuant to which, on June 3, 2024, the Company issued to the Purchaser, (i) in a registered direct offering, 5,640,958 0.001 5,640,958 0.363 5,640,958 0.363 The Shares were offered by the Company pursuant to a shelf registration statement on Form S-3 (File No. 333-262280), which was declared effective on February 4, 2022 (as amended from time to time, the “Registration Statement”). Pursuant to the terms of the Purchase Agreement, subject to certain exceptions, the Company could not issue any equity securities for 60 days following the issuance date, provided that the Company was able to utilize its at-the-market offering program with the Placement Agent after 30 days. Additionally, the Company cannot enter into a variable rate transaction (other than the ATM program with the Placement Agent) for 120 days after the issuance date. In addition, the Company’s executive officers and each of the Company’s directors have entered into lock-up agreements with the Company pursuant to which each of them has agreed not to, for a period of 90 days from the closing of the Transactions, offer, sell, transfer or otherwise dispose of the Company’s securities, subject to certain exceptions. The exercise price of the Common Warrants, and the number of Common Warrant Shares, are subject to adjustment in the event of any stock dividend or split, reverse stock split, recapitalization, reorganization or similar transaction, as described in the Common Warrants. If a Fundamental Transaction (as defined in the Common Warrants) occurs, then the successor entity will succeed to, and be substituted for the Company, and may exercise every right and power that the Company may exercise and will assume all of its obligations under the Common Warrants with the same effect as if such successor entity had been named in the warrant itself. Common Warrant Holders will have additional rights defined in the Common Warrants. The Common Warrants are exercisable on a “cashless” basis only if there is not a current registration statement permitting public resale. In this regard, the Company filed a registration statement to register the resale of the Common Warrant Shares providing for the resale of the Shares issued and issuable upon exercise of the Common Warrants. That registration statement was declared effective by the SEC on July 11, 2024. The Company has agreed to use commercially reasonable efforts to cause such registration statement to keep such registration statement effective at all times until no Purchaser owns any Warrants or Warrant Shares issuable upon exercise thereof. Maxim Group LLC acted as the placement agent (the “Placement Agent”) on a “commercially reasonable best efforts” basis, in connection with the Transactions pursuant to the Placement Agency Agreement, dated May 31, 2024 (the “Placement Agency Agreement”), by and between the Company and the Placement Agent. Pursuant to the Placement Agency Agreement, the Placement Agent was paid a cash fee of 8 The Company evaluated the Common Warrants under the guidance of ASC 480 – Distinguishing Liabilities from Equity and determined that they were in scope under the guidance as freestanding financial instruments but did not meet the criteria for liability classification and are classified as equity within the condensed consolidated financial statements. Proceeds allocated to such warrants totaled approximately $ 2.5 On September 30, 2024, the Company entered into a Securities Purchase Agreement to complete an offering with a single accredited investor. For more information see Note 15: Subsequent Events.

Net Loss Per Share

Net Loss Per Share	9 Months Ended
	Sep. 30, 2024
Earnings Per Share [Abstract]
Net Loss Per Share	Note 10: Net Loss Per Share Basic and diluted net loss per share is computed using the weighted average number of shares of common stock outstanding during the period. Equivalent common shares, consisting of stock options and warrants which amounted to 14,574,557 2,763,020

Recent Accounting Pronouncement

Recent Accounting Pronouncements	9 Months Ended
	Sep. 30, 2024
Accounting Changes and Error Corrections [Abstract]
Recent Accounting Pronouncements	Note 11: Recent Accounting Pronouncements The Company has implemented all new accounting pronouncements that are in effect. These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations. Accounting pronouncements issued by the FASB since filing the Annual Report on Form 10-K for the year ended December 31, 2023

Fair Value

Fair Value	9 Months Ended
	Sep. 30, 2024
Fair Value Disclosures [Abstract]
Fair Value	Note 12: Fair Value Fair Value The Company complies with the provisions of FASB ASC 820 “Fair Value Measurements” for its financial and non-financial assets and liabilities. ASC 820 defines fair value, establishes a framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. The fair values of cash and cash equivalents, other assets, accounts payable and accrued expenses approximate their carrying values due to the short-term maturities of these items and are considered a Level 1 instrument of the fair value measurements standard. The Company also has certain warrants with a cash settlement feature in the occurrence of a Fundamental Transaction. The fair value of the warrants (“June 2024 Warrants”) related to the Company’s June 2024 common stock and warrant issuance, are calculated using a Monte Carlo Simulation. The Company also had certain redeemable warrants in the Rights Offering with a cash settlement feature in the occurrence of a Fundamental Transaction. No Fundamental Transaction occurred. In March 2024, 205,000 5,830,028 The Company estimated the fair value of the June 2024 Warrants using the Black-Scholes Model, which uses multiple inputs including the Company’s stock price, the exercise price of the warrant, volatility of the Company’s stock price, the risk-free interest rate and the expected term of the warrants. The Company utilized the following assumptions to estimate the fair value of the Class A Warrants: Schedule of Assumptions to Estimate the Fair Value September 30, December 31, 2024 2023 Underlying price per share $ 0.350 — Exercise price per share $ 0.363 — Risk-free interest rate 4.42 % — Expected holding period 5.5 — Expected volatility 110 % — Expected dividend yield — — The Company utilized the following assumptions to estimate the fair value of the Class B Warrants: September 30, December 31, 2024 2023 Underlying price per share $ 0.350 — Exercise price per share $ 0.363 — Risk-free interest rate 4.82 % — Expected holding period 2 — Expected volatility 89 % — Expected dividend yield — — The significant assumptions using the Monte Carlo Simulation approach for valuation of the Warrants are: (i) Risk-Free Interest Rate (ii) Expected Holding Period (iii) Expected Volatility (iv) Expected Dividend Yield (v) Expected Probability of a Fundamental Transaction. 1. The Company only has one product that is FDA approved but is currently not available for commercial sales. 2. The Company will have to perform additional clinical trials for FDA approval of its flagship product. 3. Industry and market conditions continue to include uncertainty, adding risk to any transaction. 4. The nature of a life sciences company is heavily dependent on future funding and high fixed costs, including Research & Development. 5. The Company has minimal revenues streams which are insufficient to meet the funding needs for the cost of operations or construction at their manufacturing facility; and 6. The Company’s Rights Agreement and Executive Agreements make it less attractive to a potential buyer. With the above factors utilized in analysis of the likelihood of the Put’s potential Liability, the Company estimated the range of probabilities related to a Put right being triggered as: Schedule of Potential Liability Range of Probability Probability Low 0.5 % Medium 1.0 % High 5.0 % The Monte Carlo Simulation has incorporated a 5.0 (vi) Expected Timing of Announcement of a Fundamental Transaction. (vii) Expected 100 Day Volatility at Announcement of a Fundamental Transaction (viii) Expected Risk-Free Interest Rate at Announcement of a Fundamental Transaction (ix) Expected Time Between Announcement and Consummation of a Fundamental Transaction. While the assumptions remain consistent from period to period (e.g., utilizing historical stock prices), the actual historical prices input for the relevant period input change. The Company accounts for certain assets and liabilities at fair value. The hierarchy below lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market. AIM categorizes each of its fair value measurements in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. These levels are: 1. Level 1 – Quoted prices are available in active markets for identical assets or liabilities at the reporting date. Generally, this includes debt and equity securities that are traded in an active market. 2. Level 2 – Observable inputs other than Level 1 prices such as quote prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Generally, this includes debt and equity securities that are not traded in an active market. 3. Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or other valuation techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation. As of September 30, 2024, the Company has classified the warrants with cash settlement features as Level 3. Management evaluates a variety of inputs and then estimates fair value based on those inputs. As discussed above, the Company utilized the Monte Carlo Simulation Model in valuing the warrants. The table below presents the balances of assets and liabilities measured at fair value on a recurring basis by level within the hierarchy as (in thousands): Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis As of September 30, 2024 Total Level 1 Level 2 Level 3 Assets: Cash equivalents $ 67 $ 67 $ — $ — Marketable securities $ 6,287 $ 6,287 $ — $ — As of December 31, 2023 Total Level 1 Level 2 Level 3 Assets: Cash equivalents $ 4,805 $ 4,805 $ — $ — Marketable securities $ 7,631 $ 7,631 $ — $ —

Leases

Leases	9 Months Ended
	Sep. 30, 2024
Leases [Abstract]
Leases	Note 13: Leases The Company leases office and lab facilities and other equipment under non-cancellable operating leases with initial terms typically ranging from 1 5 1,000 17,000 1 5 At September 30, 2024 and December 31, 2023, the balance of the right of use assets was $ 653,000 697,000 669,000 718,000 404,000 363,000 AIM recognized rent expense associated with these leases are follows: Schedule of AIM Recognized Rent Expense Associated with Operating Lease September 30, 2024 September 30, 2023 (in thousands) September 30, 2024 September 30, 2023 Lease costs: Operating lease costs $ 226 $ 214 Short-term and variable lease costs 205 253 Total lease costs $ 431 $ 467 Classification of lease costs Research & development $ 358 $ 400 General and administrative 73 67 Total lease costs $ 431 $ 467 The Company’s leases have remaining lease terms between 6 35 32 41 10.2 10 Future minimum payments as of September 30, 2024, are as follows: Schedule of Operating Lease Future Payments Year Ending December 31, 2024 $ 78 2025 276 2026 244 2027 159 Thereafter — Less imputed interest (88 ) Total $ 669

Research, Consulting and Supply

Research, Consulting and Supply Agreements	9 Months Ended
	Sep. 30, 2024
Research Consulting And Supply Agreements
Research, Consulting and Supply Agreements	Note 14: Research, Consulting and Supply Agreements The Company has entered into research, consulting and supply agreements with third party service providers to perform research and development activities on therapeutics, including clinical trials. The identification of research and development costs involves reviewing open contracts and purchase orders, communicating with applicable company and third-party personnel to identify services that have been performed, and corroborating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of actual expenses. The Company expenses these research and development costs when incurred. During the three months ended September 30, 2024, research and development expenses were comprised of: clinical studies ($ 582,000 306,000 398,000 151,000 During the three months ended September 30, 2023, research and development expenses were comprised of: clinical studies ($ 1,916,000 396,000 251,000 170,000 During the nine months ended September 30, 2024, research and development expenses were comprised of: clinical studies ($ 1,880,000 882,000 1,232,000 540,000 During the nine months ended September 30, 2023, research and development expenses were comprised of: clinical studies ($ 3,845,000 2,783,000 752,000 359,000 The following summarizes the most substantial of our contracts relating to research, consulting, and supply costs for AIM as they related to research and development costs for the nine months ended September 30, 2024. Amarex Clinical Research LLC Amarex is the principal administrator of several of AIM’s largest clinical studies. AIM has multiple contracts with Amarex Clinical Research LLC (“Amarex”). During the three months ended September 30, 2024 and 2023, the Company incurred approximately $ 275,400 516,284 881,987 1,294,265 ● Pancreatic Cancer - In April 2022, AIM executed a work order with Amarex pursuant to which Amarex is managing a Phase 2 clinical trial in locally advanced pancreatic cancer patients designated AMP-270. Per the work order, AIM anticipates that Amarex’s management of the study will cost approximately $ 8,400,000 1,000,000 4.6 ○ During the three months ended September 30, 2024, the Company incurred approximately $ 129,000 During the three months ended September 30, 2023, the Company incurred approximately $ 82,600 ○ During the nine months ended September 30, 2024, the Company incurred approximately $ 141,100 During the nine months ended September 30, 2023, the Company incurred approximately $ 350,600 ● Post-COVID Conditions - In September 2022, AIM executed a work order with Amarex, pursuant to which Amarex is managing a Phase 2 trial in patients with Post-COVID Conditions. AIM is sponsoring the study. AIM anticipates that the study will cost approximately $ 6,400,000 125,000 4,400,000 6,600,000 ○ During the three months ended September 30, 2024, the Company incurred approximately $ 27,500 447,600 ○ During the nine months ended September 30, 2024, the Company incurred approximately $ 195,800 783,400 Jubilant HollisterStier Jubilant HollisterStier (“Jubilant”) is AIM’s authorized CMO for Ampligen for the approval in Argentina. In 2017, the Company entered into an agreement with Jubilant pursuant to which Jubilant will manufacture batches of Ampligen® for the Company. Since the 2017 engagement of Jubilant, two lots of Ampligen consisting of more than 16,000 9,042 ○ During the three months ended September 30, 2024, the Company did no no ○ During the nine months ended September 30, 2024, the Company incurred approximately $ 1,200 1,432,000 Sterling Pharma Solutions In 2022, the Company entered into a Master Service Agreement and a Quality Agreement with Sterling Pharma Solutions (“Sterling”) for the manufacture of the Company’s Poly I and Poly C12U polynucleotides and transfer of associated test methods at Sterling’s Dudley, UK location to produce the polymer precursors to manufacture the drug Ampligen. ○ During the three months ended September 30, 2024, the Company incurred approximately $ 133,000 no ○ During the nine months ended September 30, 2024, the Company incurred approximately $ 261,600 357,000 Erasmus In December 2022, the Company entered into a joint clinical study agreement with Erasmus University Medical Center Rotterdam to conduct a Phase II study: Combining anti-PD-L1 immune checkpoint inhibitor durvalumab with TLR-3 agonist rintatolimod in patients with metastatic pancreatic ductal adenocarcinoma for therapy efficacy. This is a study in collaboration with AstraZeneca. AIM’s limited responsibilities are limited to providing Ampligen. Additionally, in April 2023 AIM agreed to provide to Erasmus MC an unrestricted grant of $ 200,000 ○ During the three months ended September 30, 2024, the Company did no During the three months ended September 30, 2023, the Company did no ○ During the nine months ended September 30, 2024, the Company incurred approximately $ 79,000 During the nine months ended September 30, 2023, the Company incurred approximately $ 100,000 Azenova Sales International In October 2023, the Company entered into a consulting agreement with Azenova, LLC whereas Azenova will provide business development services for AIM’s Ampligen product for solid tumors for a 12-month term that is extendable upon the agreement of the parties. In exchange for its services, Azenova will receive a fixed monthly retainer of $ 30,000 360,000 10,000 ○ During the three months ended September 30, 2024, the Company incurred approximately $ 50,000 no ○ During the nine months ended September 30, 2024, the Company incurred approximately $ 230,000 no Alcami In September 2023, the Company entered into an agreement with Alcami Corporation to perform an extractables study for a primary packaging component. The agreement called for fixed costs of approximately $ 30,000 ○ During the three months ended September 30, 2024, the Company did no During the three months ended September 30, 2023, the Company incurred approximately $ 8,800 ○ During the nine months ended September 30, 2024, the Company incurred approximately $ 14,000 25,000

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2024
Subsequent Events [Abstract]
Subsequent Events	Note 15: Subsequent Events On September 30, 2024, the Company entered into a Securities Purchase Agreement (the “ Purchase Agreement Transactions Purchaser 4,653,036 Shares 0.001 Common Stock 4,653,036 C Warrants 0.28 4,653,036 D Warrants Common Warrants 0.28 Securities Act The Company received aggregate gross proceeds from the Transactions of approximately $ 1.26 Registration Statement Pursuant to the terms of the Purchase Agreement, subject to certain exceptions, the Company cannot issue any equity securities for 60 days following the closing of the Transactions (the “ Closing Date ATM The exercise price of the Common Warrants, and the number of shares of Common Stock underling the Common Warrant (the “ Common Warrant Shares The Company is currently evaluating the Common Warrants under the guidance of ASC 480 – Distinguishing Liabilities from Equity

Property and Equipment, net (Ta

Property and Equipment, net (Tables)	9 Months Ended
	Sep. 30, 2024
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Schedule of Property and Equipment (in thousands) September 30, 2024 December 31, 2023 Furniture, fixtures, and equipment 1,466 1,448 Less: accumulated depreciation (1,349 ) (1,321 ) Property and equipment, net $ 117 $ 127

Patents, and Trademark Rights_2

Patents, and Trademark Rights, Net (Tables)	9 Months Ended
	Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Patent and Trademark Rights	Patent and trademark rights consist of the following (in thousands): Schedule of Patent and Trademark Rights September 30, 2024 December 31, 2023 Gross Carrying Value Accumulated Amortization Net Carrying Value Gross Carrying Value Accumulated Amortization Net Carrying Value Patents $ 3,315 $ (887 ) $ 2,428 $ 2,947 $ (750 ) $ 2,197 Trademarks 232 (128 ) 104 229 (113 ) 116 Net amortizable patents and trademarks rights $ 3,547 $ (1,015 ) $ 2,532 $ 3,176 $ (863 ) $ 2,313
Schedule of Changes in Patents, Trademark Rights	Patent and trademark rights acquisitions, abandonments and amortization: Schedule of Changes in Patents, Trademark Rights December 31, 2023 $ 2,313 Acquisitions 419 Abandonments and expirations (46 ) Amortization (154 ) September 30, 2024 $ 2,532
Schedule of Amortization of Patents and Trademarks	Amortization of patents and trademarks for each of the next five years and thereafter is as follows (in thousands): Schedule of Amortization of Patents and Trademarks Year Ending December 31, 2024 $ 72 2025 268 2026 265 2027 239 2028 219 Thereafter 1,469 Total $ 2,532

Accrued Expenses (Tables)

Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2024
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses consist of the following: Schedule of Accrued Expenses (in thousands) September 30, 2024 December 31, 2023 Compensation $ 1 $ 414 Professional fees 790 1,352 Clinical trial expenses 132 184 Interest 51 — Other expenses 37 36 Total $ 1,011 $ 1,986

Unsecured Promissory Note (Tabl

Unsecured Promissory Note (Tables)	9 Months Ended
	Sep. 30, 2024
Debt Disclosure [Abstract]
Schedule of Long Term Debt	Schedule of Long Term Debt Debt schedule at September 30, 2024 (in thousands) Long-term debt $ 3,301 Unamortized Original issue discount (555 ) Unamortized Financing fees (14 ) Unamortized discount and debt issuance costs 2,732 Less current portion of long-term debt, net (2,593 ) Long-term debt, net $ 139

Equity-Based Compensation (Tabl

Equity-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2024
Share-Based Payment Arrangement, Employee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Schedule of Stock Option Activity	Stock option activity for employees: Schedule of Stock Option Activity Number of Weighted Weighted Aggregate Outstanding June 30, 2024 2,407,775 $ 2.50 8.70 $ — Granted — — — — Forfeited — — — — Expired (95 ) — — — Outstanding September 30, 2024 2,407,680 $ 2.44 8.70 $ — Vested and expected to vest September 30, 2024 2,407,680 $ 2.44 8.70 $ — Exercisable September 30, 2024 2,341,014 $ 1.66 7.17 $ — Number of Weighted Weighted Aggregate Outstanding January 1, 2024 2,408,438 $ 2.50 8.70 $ — Granted — — — — Forfeited — — — — Expired (758 ) — — — Outstanding September 30, 2024 2,407,680 $ 2.44 8.70 $ — Vested and expected to vest September 30, 2024 2,407,680 $ 2.44 8.70 $ — Exercisable September 30, 2024 2,341,014 $ 1.66 7.17 $ —
Schedule of Unvested Stock Option Activity	Unvested stock option activity for employees: Schedule of Unvested Stock Option Activity Number of Weighted Weighted Aggregate Unvested June 30, 2024 166,666 $ 4.11 18.87 $ — Granted — — — — Expired (95 ) — — — Vested (99,905 ) 0.47 7.17 — Unvested September 30, 2024 66,666 $ 9.61 36.22 $ — Number of Weighted Weighted Aggregate Unvested January 1, 2024 366,666 $ 2.13 12.44 $ — Granted — — — — Expired (758 ) — — — Vested (299,242 ) 0.47 7.17 — Unvested September 30, 2024 66,666 $ 9.61 36.22 $ —
Share-Based Payment Arrangement, Nonemployee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Schedule of Stock Option Activity	Stock option activity for non-employees: Schedule of Stock Option Activity Number of Weighted Weighted Aggregate Outstanding June 30, 2024 885,055 $ 2.02 9.23 $ — Granted — — — — Forfeited — — — — Expired (95 ) — — — Outstanding September 30, 2024 884,960 $ 1.88 9.23 $ — Vested and expected to vest September 30, 2024 884,960 $ 1.88 9.23 $ — Exercisable September 30, 2024 729,960 $ 1.87 10.06 $ — Number of Weighted Weighted Aggregate Outstanding January 1, 2024 885,055 $ 2.02 9.23 $ — Granted — — — — Forfeited — — — — Expired (95 ) — — — Outstanding September 30, 2024 884,960 $ 1.88 9.23 $ — Vested and expected to vest September 30, 2024 884,960 $ 1.88 9.23 $ — Exercisable September 30, 2024 729,960 $ 1.87 10.06 $ —
Schedule of Unvested Stock Option Activity	Unvested stock option activity for non-employees: Schedule of Unvested Stock Option Activity Number of Weighted Weighted Aggregate Unvested June 30, 2024 155,001 $ 3.42 11.30 $ — Granted — — — — Expired (95 ) — — — Vested 95 0.46 10.18 — Unvested September 30, 2024 155,001 $ 3.42 11.31 $ — Number of Weighted Weighted Aggregate Unvested January 1, 2024 335,001 $ 1.83 10.70 $ — Granted — — — — Expired (95 ) — — — Vested (179,905 ) 0.46 10.18 — Unvested September 30, 2024 155,001 $ 3.42 11.31 $ —

Fair Value (Tables)

Fair Value (Tables)	9 Months Ended
	Sep. 30, 2024
Fair Value Disclosures [Abstract]
Schedule of Assumptions to Estimate the Fair Value	The Company utilized the following assumptions to estimate the fair value of the Class A Warrants: Schedule of Assumptions to Estimate the Fair Value September 30, December 31, 2024 2023 Underlying price per share $ 0.350 — Exercise price per share $ 0.363 — Risk-free interest rate 4.42 % — Expected holding period 5.5 — Expected volatility 110 % — Expected dividend yield — — The Company utilized the following assumptions to estimate the fair value of the Class B Warrants: September 30, December 31, 2024 2023 Underlying price per share $ 0.350 — Exercise price per share $ 0.363 — Risk-free interest rate 4.82 % — Expected holding period 2 — Expected volatility 89 % — Expected dividend yield — —
Schedule of Potential Liability	With the above factors utilized in analysis of the likelihood of the Put’s potential Liability, the Company estimated the range of probabilities related to a Put right being triggered as: Schedule of Potential Liability Range of Probability Probability Low 0.5 % Medium 1.0 % High 5.0 %
Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis	The table below presents the balances of assets and liabilities measured at fair value on a recurring basis by level within the hierarchy as (in thousands): Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis As of September 30, 2024 Total Level 1 Level 2 Level 3 Assets: Cash equivalents $ 67 $ 67 $ — $ — Marketable securities $ 6,287 $ 6,287 $ — $ — As of December 31, 2023 Total Level 1 Level 2 Level 3 Assets: Cash equivalents $ 4,805 $ 4,805 $ — $ — Marketable securities $ 7,631 $ 7,631 $ — $ —

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2024
Leases [Abstract]
Schedule of AIM Recognized Rent Expense Associated with Operating Lease	AIM recognized rent expense associated with these leases are follows: Schedule of AIM Recognized Rent Expense Associated with Operating Lease September 30, 2024 September 30, 2023 (in thousands) September 30, 2024 September 30, 2023 Lease costs: Operating lease costs $ 226 $ 214 Short-term and variable lease costs 205 253 Total lease costs $ 431 $ 467 Classification of lease costs Research & development $ 358 $ 400 General and administrative 73 67 Total lease costs $ 431 $ 467
Schedule of Operating Lease Future Payments	Future minimum payments as of September 30, 2024, are as follows: Schedule of Operating Lease Future Payments Year Ending December 31, 2024 $ 78 2025 276 2026 244 2027 159 Thereafter — Less imputed interest (88 ) Total $ 669

Cash and Cash Equivalents (Deta

Cash and Cash Equivalents (Details Narrative)	Sep. 30, 2024 USD ($)
Cash and Cash Equivalents [Abstract]
Federlly insured limit	$ 250,000

Marketable Securities (Details

Marketable Securities (Details Narrative) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Investments, Debt and Equity Securities [Abstract]
Held value of marketable securities	$ 6,287,000	$ 7,631,000
Marketable securities	$ 6,287,000	$ 7,631,000
Equity securities description	The net gain recognized for the three-month period ended September 30, 2024 on equity securities was $273,000. The net losses recognized for the three-month period ended September 30, 2024 on equity securities sold during the period were ($59,000). The unrealized gains recognized for the three-month period ended September 30, 2024 on equity securities still held was $332,000. The net gain recognized for the nine-month period ended September 30, 2024 on equity securities was $96,000. The net losses recognized for the nine-month period ended September 30, 2024 on equity securities sold during the period were ($277,000). The unrealized gains recognized for the nine-month period ended September 30, 2024 on equity securities still held was $373,000.	The net loss recognized for the three-month period ended September 30, 2023 on equity securities was ($309,000).  The net losses recognized for the three-month period ended September 30, 2023 on equity securities sold during the period were ($42,000). The unrealized losses recognized during the three-month period ended September 30, 2023 on equity securities still held was ($267,000). The net losses recognized for the nine-month period ended September 30, 2023 on equity securities was ($201,000). The net losses recognized for the nine-month period ended September 30, 2023 on equity securities sold during the period were ($130,000). The unrealized losses recognized during the nine-month period ended September 30, 2023 on equity securities still held was ($71,000).

Schedule of Property and Equipm

Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
Furniture, fixtures, and equipment	$ 1,466	$ 1,448
Less: accumulated depreciation	(1,349)	(1,321)
Property and equipment, net	$ 117	$ 127

Property and Equipment, net (De

Property and Equipment, net (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Property, Plant and Equipment [Line Items]
Depreciation expense	$ 28,000	$ 30,000
Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	3 years
Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	10 years

Schedule of Patent and Trademar

Schedule of Patent and Trademark Rights (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Finite-Lived Intangible Assets [Line Items]
Gross carrying value	$ 3,547	$ 3,176
Accumulated amortization	(1,015)	(863)
Net carrying value	2,532	2,313
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying value	3,315	2,947
Accumulated amortization	(887)	(750)
Net carrying value	2,428	2,197
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying value	232	229
Accumulated amortization	(128)	(113)
Net carrying value	$ 104	$ 116

Schedule of Changes in Patents,

Schedule of Changes in Patents, Trademark Rights (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Balance	$ 2,313
Acquisitions	419
Abandonments	(46)
Accumulated Amortization	(154)	$ (150)
Balance	$ 2,532

Schedule of Amortization of Pat

Schedule of Amortization of Patents and Trademarks (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
2024	$ 72
2025	268
2026	265
2027	239
2028	219
Thereafter	1,469
Total	$ 2,532	$ 2,313

Patents, and Trademark Rights_3

Patents, and Trademark Rights, Net (Details Narrative)	9 Months Ended
	Sep. 30, 2024
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Finite lived intangible assets, estimated useful life	17 years
Finite lived intangible assets, weighted average amortization	12 years
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Finite lived intangible assets, estimated useful life	10 years
Finite lived intangible assets, weighted average amortization	6 years

Schedule of Accrued Expenses (D

Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Payables and Accruals [Abstract]
Compensation	$ 1	$ 414
Professional fees	790	1,352
Clinical trial expenses	132	184
Interest	51
Other expenses	37	36
Total	$ 1,011	$ 1,986

Schedule of Long Term Debt (Det

Schedule of Long Term Debt (Details) $ in Thousands	Sep. 30, 2024 USD ($)
Debt Disclosure [Abstract]
Long-term debt	$ 3,301
Unamortized Original issue discount	(555)
Unamortized Financing fees	(14)
Unamortized discount and debt issuance costs	2,732
Less current portion of long-term debt, net	(2,593)
Long-term debt, net	$ 139

Unsecured Promissory Note (Deta

Unsecured Promissory Note (Details Narrative) - USD ($)		9 Months Ended
	Feb. 16, 2024	Sep. 30, 2024	Dec. 31, 2023
Line of Credit Facility [Line Items]
Long term debt		$ 3,301,000
Unsecured debt			$ 0
Interest expense debt excluding amortization		226,000
Amortization expenses of long term debt		232,000
Original issue discount		226,000
Loan fee amortization		6,000
Future maturities of long term debt		750,000
Future maturities of long term debt		2,551,000
Long-term debt, current		3,000,000
Debt discount, current		397,000
Debt origination costs, current		10,000
Long-term debt, non current		301,000
Debt discount, non current		159,000
Debt origination costs, non current		$ 3,000
Note Purchase Agreement [Member] | Streeterville Capital LLC [Member]
Line of Credit Facility [Line Items]
Exchange of unsecured promissory notes	$ 2,500,000
Unsecured debt original issue discount	781,250
Long term debt	3,301,250
Debt issuance costs	$ 20,000
Debt instrument stated interest rate	10%
Redemption description	The agreement allows the Lender to redeem up to $250,000 per calendar month beginning in August 2024, upon providing written notice to Borrower.

Schedule of Stock Option Activi

Schedule of Stock Option Activity (Details) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2024
Share-Based Payment Arrangement, Employee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options Outstanding, Beginning of Period	2,407,775	2,408,438
Weighted Average Exercise Price Outstanding, Beginning of Period	$ 2.50	$ 2.50
Weighted Average Remaining Contracted Term (years) Outstanding	8 years 8 months 12 days	8 years 8 months 12 days
Aggregate Intrinsic Value Outstanding, Beginning of Period
Number of Options, Granted
Weighted Average Exercise Price, Granted
Aggregate Intrinsic Value, Granted
Number of Options, Forfeited
Weighted Average Exercise Price, Forfeited
Aggregate Intrinsic Value, Forfeited
Number of Options, Expired	(95)	(758)
Weighted Average Exercise Price, Expired
Aggregate Intrinsic Value, Expired
Number of Options Outstanding, Ending of Period	2,407,680	2,407,680
Weighted Average Exercise Price Outstanding, End of Period	$ 2.44	$ 2.44
Weighted Average Remaining Contracted Term (years) Outstanding	8 years 8 months 12 days	8 years 8 months 12 days
Aggregate Intrinsic Value Outstanding, Ending of Period
Number of Options, Vested and Expected to Vest	2,407,680	2,407,680
Weighted Average Exercise Price, Vested and Expected to Vest	$ 2.44	$ 2.44
Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest	8 years 8 months 12 days	8 years 8 months 12 days
Aggregate Intrinsic Value, Vested and Expected to Vest
Number of Options Exercisable, End of Period	2,341,014	2,341,014
Weighted Average Exercise Price Exercisable, Ending of Period	$ 1.66	$ 1.66
Weighted Average Remaining Contracted Term (years), Exercisable at End of Period	7 years 2 months 1 day	7 years 2 months 1 day
Aggregate Intrinsic Value, Exercisable at End of Period
Share-Based Payment Arrangement, Nonemployee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options Outstanding, Beginning of Period	885,055	885,055
Weighted Average Exercise Price Outstanding, Beginning of Period	$ 2.02	$ 2.02
Weighted Average Remaining Contracted Term (years) Outstanding	9 years 2 months 23 days	9 years 2 months 23 days
Aggregate Intrinsic Value Outstanding, Beginning of Period
Number of Options, Granted
Weighted Average Exercise Price, Granted
Aggregate Intrinsic Value, Granted
Number of Options, Forfeited
Weighted Average Exercise Price, Forfeited
Aggregate Intrinsic Value, Forfeited
Number of Options, Expired	(95)	(95)
Weighted Average Exercise Price, Expired
Number of Options Outstanding, Ending of Period	884,960	884,960
Weighted Average Exercise Price Outstanding, End of Period	$ 1.88	$ 1.88
Weighted Average Remaining Contracted Term (years) Outstanding	9 years 2 months 23 days	9 years 2 months 23 days
Aggregate Intrinsic Value Outstanding, Ending of Period
Number of Options, Vested and Expected to Vest	884,960	884,960
Weighted Average Exercise Price, Vested and Expected to Vest	$ 1.88	$ 1.88
Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest	9 years 2 months 23 days	9 years 2 months 23 days
Aggregate Intrinsic Value, Vested and Expected to Vest
Number of Options Exercisable, End of Period	729,960	729,960
Weighted Average Exercise Price Exercisable, Ending of Period	$ 1.87	$ 1.87
Weighted Average Remaining Contracted Term (years), Exercisable at End of Period	10 years 21 days	10 years 21 days
Aggregate Intrinsic Value, Expired

Schedule of Unvested Stock Opti

Schedule of Unvested Stock Option Activity (Details) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2024
Share-Based Payment Arrangement, Employee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options Unvested, Beginning of Period	166,666	366,666
Weighted Average Exercise Price Unvested, Beginning of Period	$ 4.11	$ 2.13
Average Remaining Contractual Term (years) Unvested, Beginning of Period	18 years 10 months 13 days	12 years 5 months 8 days
Aggregate Intrinsic Value Unvested, Beginning of Period
Number of Options, Granted
Weighted Average Exercise Price, Granted
Aggregate Intrinsic Value, Granted
Number of Options, Expired	(95)	(758)
Weighted Average Exercise Price, Expired
Aggregate Intrinsic Value, Expired
Number of Options, Vested	(99,905)	(299,242)
Weighted Average Exercise Price, Vested	$ 0.47	$ 0.47
Average Remaining Contractual Term Vested	7 years 2 months 1 day	7 years 2 months 1 day
Aggregate Intrinsic Value, Vested
Number of Options Unvested, End of Period	66,666	66,666
Weighted Average Exercise Price Unvested, Ending of Period	$ 9.61	$ 9.61
Weighted Average Remaining Contracted Term (years), Exercisable at End of Period	36 years 2 months 19 days	36 years 2 months 19 days
Aggregate Intrinsic Value Unvested, End of Period
Number of Options, Vested	99,905	299,242
Share-Based Payment Arrangement, Nonemployee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options Unvested, Beginning of Period	155,001	335,001
Weighted Average Exercise Price Unvested, Beginning of Period	$ 3.42	$ 1.83
Average Remaining Contractual Term (years) Unvested, Beginning of Period	11 years 3 months 18 days	10 years 8 months 12 days
Aggregate Intrinsic Value Unvested, Beginning of Period
Number of Options, Granted
Weighted Average Exercise Price, Granted
Aggregate Intrinsic Value, Granted
Number of Options, Expired	(95)	(95)
Weighted Average Exercise Price, Expired
Aggregate Intrinsic Value, Expired
Number of Options, Vested	(95)	(179,905)
Weighted Average Exercise Price, Vested	$ 0.46	$ 0.46
Average Remaining Contractual Term Vested	10 years 2 months 4 days	10 years 2 months 4 days
Aggregate Intrinsic Value, Vested
Number of Options Unvested, End of Period	155,001	155,001
Weighted Average Exercise Price Unvested, Ending of Period	$ 3.42	$ 3.42
Weighted Average Remaining Contracted Term (years), Exercisable at End of Period	11 years 3 months 21 days	11 years 3 months 21 days
Aggregate Intrinsic Value Unvested, End of Period
Number of Options, Vested	95	179,905

Equity-Based Compensation (Deta

Equity-Based Compensation (Details Narrative) - USD ($)		3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 12, 2018	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Jul. 01, 2024	Jul. 01, 2023	Jul. 01, 2022	Jul. 01, 2021	Aug. 03, 2020
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stockholders equity reverse stock split										one year (39,266 options post reverse split).	(27,028 options post reverse split)
Share based compensation expense		$ 80,000	$ 50,000	$ 490,000	$ 182,000
Share based compensation expense				490,000	182,000
Stock issued as payroll, value		250,000		250,000
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount		$ 53,400	$ 35,000	$ 53,400	$ 35,000
2018 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stockholders equity reverse stock split	44:1 reverse stock split
Number of stock is reserved for potential issuance	230,390	5,167,160		5,167,160								1,142,733	968,389	960,976	956,660	685,012
Option vested years	10 years
2018 Equity Incentive Plan [Member] | Officer [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of options granted				0	0	400,000	850,000	613,512	1,025,000	1,727,756	1,189,284
Exercise price range						$ 0.47				$ 9.68	$ 9.68
Expiration period						10 years	10 years	10 years	10 years	10 years	10 years
2018 Equity Incentive Plan [Member] | Officer [Member] | Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price range							$ 0.31	$ 1.11	$ 2.77
2018 Equity Incentive Plan [Member] | Officer [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price range							$ 0.71	$ 1.71	$ 3.07
Restated 2018 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of stock is reserved for potential issuance	250,000

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($)								1 Months Ended		3 Months Ended						9 Months Ended		12 Months Ended
	Jun. 03, 2024	Mar. 28, 2024	Apr. 19, 2023	Jul. 07, 2020	Mar. 31, 2020	Sep. 27, 2019	Sep. 25, 2019	May 31, 2024	Apr. 30, 2024	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2020	May 10, 2023	May 09, 2023
Class of Stock [Line Items]
Preferred stock, shares authorized										5,000,000						5,000,000
Preferred stock, par value										$ 0.01						$ 0.01
Preferred stock conversion price										0.20						0.20
Exercise price										$ 8.80						$ 8.80
Warrants issued										114						114
Common stock, shares authorized										350,000,000						350,000,000		350,000,000
Common stock specific limitations and restrictions on usage										8,000,000						8,000,000
Common stock, shares issued										58,668,647						58,668,647		49,102,484
Common stock, shares outstanding										58,668,647						58,668,647		49,102,484
Issuance of common stock										$ 180,000	$ 532,000	$ 329,000	$ 233,000	$ 5,000	$ 100,000
Warrants exercised aggregate												205,000
Proceeds from issuance or sale of equity																$ 860,000	$ 338,000
Warrant gross proceeds					$ 264,000
Warrant modification					$ 46,000
Class of Warrant or Right, Outstanding										0						0		152,160
Common stock, par value										$ 0.001						$ 0.001		$ 0.001
Proceeds from warrants										$ 2,500,000						$ 2,500,000
Placement Agent [Member]
Class of Stock [Line Items]
Aggregate gross proceeds, percentage								8%
Purchase Agreement [Member]
Class of Stock [Line Items]
Number of stock sold									9,975,000							759,685
Amount of stock sold																$ 128,000
Purchase Agreement [Member] | Atlas Sciences LLC [Member]
Class of Stock [Line Items]
Equity investment ownership percentage		19.99%
Alliance Global Partners, LLC [Member]
Class of Stock [Line Items]
Warrants issued						7,148,310
Number of shares issued upon transaction						1,740,550
Proceeds from issuance or sale of equity							$ 7,200,000
Maxim Group LLC [Member] | Equity Distribution Agreement [Member]
Class of Stock [Line Items]
Issuance of common stock			$ 8,500,000
Proceeds from issuance of common stock										$ 4,110						$ 630,204		$ 344,000
Aggregate gross proceeds, percentage			3%							3%						3%		3%
Number of stock sold										10,975						1,305,653		598,114
Amount of stock sold										$ 123						$ 18,906		$ 10,326
Atlas Sciences LLC [Member] | Purchase Agreement [Member]
Class of Stock [Line Items]
Number of stock sold									9,636,400
Market price, percentage		95%
Trading maximum lessor amount		$ 500,000
Beneficial ownership percentage		4.99%
Commitment shares issued									$ 338,600
Directors, Officers and Employees [Member]
Class of Stock [Line Items]
Issuance of common stock				$ 500,000
Common Stock [Member]
Class of Stock [Line Items]
Exercise price										$ 8.80						$ 8.80
Issuance of common stock										$ 1,000	$ 7,000	$ 1,000
Number of shares issued upon transaction										653,430	6,884,747	807,577	377,959	11,937	322,583
Pre-funded warrants exercised										878,537
Common Stock [Member] | Atlas Sciences LLC [Member] | Purchase And Registration Rights Agreement [Member]
Class of Stock [Line Items]
Issuance of common stock		$ 15,000,000
Warrants [Member] | Alliance Global Partners, LLC [Member]
Class of Stock [Line Items]
Warrants exercised aggregate						8,888,860
Representative Warrants [Member] | Alliance Global Partners, LLC [Member]
Class of Stock [Line Items]
Warrants expired										15,000						5,830,028
Representative Warrants [Member] | Maximum [Member] | Alliance Global Partners, LLC [Member]
Class of Stock [Line Items]
Warrants exercised aggregate					266,665	266,665
Pre-Funded Warrants [Member]
Class of Stock [Line Items]
Exercise price						$ 0.001
Shares issued price per share						$ 0.899
Percentage of outstanding stock						4.99%
Pre-funded warrants exercised																			1,870,000
Pre-Funded Warrants [Member] | Alliance Global Partners, LLC [Member]
Class of Stock [Line Items]
Shares issued price per share						$ 0.90
Warrant [Member]
Class of Stock [Line Items]
Exercise price						$ 0.99
Pre-funded warrants exercised										0						205,000			8,873,960
Rights [Member]
Class of Stock [Line Items]
Subscription price										$ 1,000						$ 1,000
Convertible preferred stock face value										$ 1,000						1,000
Net proceeds from warrants																$ 4,700,000
Series A Junior Participating Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized										4,000,000						4,000,000		250,000		250,000	4,000,000
Preferred stock, par value										$ 0.001						$ 0.001		$ 0.001
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized										10,000						10,000		10,000
Preferred stock, par value										$ 0.01						$ 0.01
Preferred stock, stated value										$ 1,000						$ 1,000		$ 1,000
Conversion of shares issued																689
Common Stock [Member]
Class of Stock [Line Items]
Number of shares issued upon transaction										0			62,841			335,603	385,424
Proceeds from issuance of common stock													$ 35,500			$ 120,000	$ 135,000
Common Stock [Member] | Securities Purchase Agreement [Member]
Class of Stock [Line Items]
Number of shares issued upon transaction	5,640,958
Common stock, par value	$ 0.001
Common Stock [Member] | Minimum [Member]
Class of Stock [Line Items]
Shares issued price per share										$ 0.33			$ 0.44			$ 0.33	$ 0.44
Shares issued price per share													0.31				0.31
Common Stock [Member] | Maximum [Member]
Class of Stock [Line Items]
Shares issued price per share										$ 0.41			0.67			$ 0.41	0.67
Shares issued price per share													$ 0.67				$ 0.67
Warrant [Member] | Securities Purchase Agreement [Member]
Class of Stock [Line Items]
Exercise price	$ 0.363
Number of shares issued upon transaction	5,640,958
Class B Common Warrants [Member] | Securities Purchase Agreement [Member]
Class of Stock [Line Items]
Exercise price	$ 0.363
Number of shares issued upon transaction	5,640,958

Net Loss Per Share (Details Nar

Net Loss Per Share (Details Narrative) - shares	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Net loss per share, antidilutive	14,574,557	2,763,020

Schedule of Assumptions to Esti

Schedule of Assumptions to Estimate the Fair Value (Details)	Sep. 30, 2024	Dec. 31, 2023
Measurement Input, Share Price [Member] | Class A Warrant [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected dividend yield	0.350
Measurement Input, Share Price [Member] | Class B Warrant [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected dividend yield	0.350
Measurement Input, Exercise Price [Member] | Class A Warrant [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected dividend yield	0.363
Measurement Input, Exercise Price [Member] | Class B Warrant [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected dividend yield	0.363
Measurement Input, Risk Free Interest Rate [Member] | Class A Warrant [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected dividend yield	4.42
Measurement Input, Risk Free Interest Rate [Member] | Class B Warrant [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected dividend yield	4.82
Measurement Input, Expected Term [Member] | Class A Warrant [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected holding period	5 years 6 months
Measurement Input, Expected Term [Member] | Class B Warrant [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected holding period	2 years
Measurement Input, Price Volatility [Member] | Class A Warrant [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected dividend yield	1.10
Measurement Input, Price Volatility [Member] | Class B Warrant [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected dividend yield	0.89
Measurement Input, Expected Dividend Rate [Member] | Class A Warrant [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected dividend yield
Measurement Input, Expected Dividend Rate [Member] | Class B Warrant [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected dividend yield

Schedule of Potential Liability

Schedule of Potential Liability (Details)	9 Months Ended
	Sep. 30, 2024
Fair Value Disclosures [Abstract]
Low range, rate	0.50%
Medium range, rate	1%
High range, rate	5%

Schedule of Assets and Liabilit

Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents-Marketable investments	$ 67	$ 4,805
Marketable securities	6,287	7,631
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents-Marketable investments	67	4,805
Marketable securities	6,287	7,631
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents-Marketable investments
Marketable securities
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents-Marketable investments
Marketable securities

Fair Value (Details Narrative)

Fair Value (Details Narrative) - shares	9 Months Ended
	Sep. 30, 2024	Mar. 31, 2024
Fair Value Disclosures [Abstract]
Conversion of warrants		205,000
Cashless basis, expired		5,830,028
Probability, rate	5%

Schedule of AIM Recognized Rent

Schedule of AIM Recognized Rent Expense Associated with Operating Lease (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Lease costs:
General and administrative	$ 226	$ 214
Short-term and variable lease costs	205	253
Total lease costs	431	467
Research and Development Expense [Member]
Lease costs:
General and administrative	358	400
General and Administrative Expense [Member]
Lease costs:
General and administrative	$ 73	$ 67

Schedule of Operating Lease Fut

Schedule of Operating Lease Future Payments (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Leases [Abstract]
2024	$ 78,000
2025	276,000
2026	244,000
2027	159,000
Thereafter
Less imputed interest	88,000
Total	$ 669,000	$ 718,000

Leases (Details Narrative)

Leases (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Right of use asset	$ 653,000	$ 697,000
Lease liability	669,000	718,000
Accumulated amortization	$ 404,000	$ 363,000
Lessee, operating lease, remaining lease term		41 months
Operating lease, weighted average remaining lease term	32 months
Debt, weighted average interest rate	10.20%	10%
Minimum [Member]
Operating lease term	1 year
Operating lease Payment	$ 1,000
Lessee, operating lease, remaining lease term	6 months
Maximum [Member]
Operating lease term	5 years
Operating lease Payment	$ 17,000
Lessee, operating lease, remaining lease term	35 months

Research, Consulting and Supp_2

Research, Consulting and Supply Agreements (Details Narrative)	1 Months Ended					3 Months Ended		9 Months Ended		12 Months Ended
	Aug. 31, 2024 USD ($)	Sep. 30, 2023 USD ($)	Apr. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Apr. 30, 2022 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Dec. 31, 2023 USD ($) Integer	Dec. 31, 2017 Integer	Oct. 31, 2023 USD ($) shares
Research and development expense						$ 1,437,000	$ 2,734,000	$ 4,533,000	$ 7,739,000
Amarex Clinical Research LLC [Member]
Research and development expense						275,400	516,284	881,987	1,294,265
Research and development expense excluding acquired in process cost				$ 6,400,000	$ 8,400,000
Development cost				125,000	$ 1,000,000					$ 6,600,000
Estimated lives					4 years 7 months 6 days
Invigilators cost				$ 4,400,000
Amarex Clinical Research LLC [Member] | Advanced Pancreatic Cancer Study Agreement [Member]
Research and development expense						129,000	82,600	141,100	350,600
Amarex Clinical Research LLC [Member] | Post COVID Study Agreement [Member]
Research and development expense						27,500	447,600	195,800	783,400
Jubilant HollisterStier [Member]
Number of units manufactured | Integer											16,000
Additional number of vials | Integer										9,042
Jubilant HollisterStier [Member] | Ampligen Manufacturing Agreement [Member]
Research and development expense						0	0	1,200	1,432,000
Sterling Pharma Solutions [Member] | Master Service Agreement and Quality Agreement [Member]
Research and development expense						133,000	0	261,600	357,000
Erasmus University Medical Center [Member] | Joint Clinical Study Agreement [Member]
Research and development expense						0	0	79,000	100,000
Unrestricted grants			$ 200,000
Azenova LLC [Member] | Consulting Agreement [Member]
Research and development expense						50,000	0	230,000	0
Stock options, aggregate intrinsic value												$ 30,000
Stock options, vested | shares												360,000
Monthly retainer fee	$ 10,000
Alcami Corporation [Member]
Research and development expense							8,800	14,000	25,000
Research and development expense		$ 30,000
Clinical Studies [Member]
Research and development expense						582,000	1,916,000	1,880,000	3,845,000
Manufacturing and Engineering [Member]
Research and development expense						306,000	396,000	882,000	2,783,000
Quality Control [Member]
Research and development expense						398,000	251,000	1,232,000	752,000
Regulatory [Member]
Research and development expense						$ 151,000	$ 170,000	$ 540,000	$ 359,000

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)			3 Months Ended
	Oct. 01, 2024	Mar. 31, 2020	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2023
Subsequent Event [Line Items]
Common stock, par value			$ 0.001						$ 0.001
Exercise price			$ 8.80
Grosss proceeds		$ 264,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Grosss proceeds	$ 1,260,000
Common Stock [Member]
Subsequent Event [Line Items]
Number of shares issued upon transaction			653,430	6,884,747	807,577	377,959	11,937	322,583
Exercise price			$ 8.80
Securities Purchase Agreement [Member] | Subsequent Event [Member] | Class C Common Warrant [Member]
Subsequent Event [Line Items]
Number of shares issued upon transaction	4,653,036
Exercise price	$ 0.28
Securities Purchase Agreement [Member] | Subsequent Event [Member] | Class D Common Warrant [Member]
Subsequent Event [Line Items]
Number of shares issued upon transaction	4,653,036
Exercise price	$ 0.28
Securities Purchase Agreement [Member] | Common Stock [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Number of shares issued upon transaction	4,653,036
Common stock, par value	$ 0.001